Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 18, 2015 4:14 AM ET

Healthcare Equipment and Supplies

Company Overview of Veracyte, Inc.

Company Overview

Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the P...

7000 Shoreline Court

Suite 250

South San Francisco, CA 94080

United States

Founded in 2006

167 Employees





Key Executives for Veracyte, Inc.

Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee
Age: 56
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting Officer and Member of Non-Management Equity Award Committee
Age: 54
Total Annual Compensation: $300.0K
Chief Operating Officer
Age: 45
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

Veracyte, Inc. Key Developments

Veracyte, Inc. Initiates Launch of Percepta™ Bronchial Genomic Classifier to Improve Lung Cancer Diagnosis

Veracyte, Inc. announced the launch of its Percepta™ Bronchial Genomic Classifier, a new genomic test to resolve ambiguity in lung cancer diagnosis. The company will soon begin testing patient samples in its CLIA-certified laboratory, with the Percepta test now available to a limited number of institutions around the country. The Percepta test is designed to reduce the number of invasive biopsies and other procedures that can follow when suspicious lung nodules are found on computerized tomography (CT) scans. The test is used when results from a bronchoscopy - a common nonsurgical procedure to evaluate lung nodules - are non-diagnostic, meaning that cancer cannot be ruled out. Data from a prospective, multicenter clinical validation study previously demonstrated the Percepta test's ability to identify patients whose lung nodules are at low risk of malignancy so that they can be monitored with CT scans in lieu of invasive diagnostic procedures. Veracyte's test comprises a 23-gene molecular classifier that uses proprietary "field of injury" technology to detect molecular changes that occur in the epithelial cells lining the lung's respiratory tract in response to smoking - the cause of 85-90% of lung cancers. These changes can be detected in cells obtained from standard cytology brushings taken during bronchoscopy from the proximal airway, and indicate the presence of malignancy or disease processes from distant sites in the lung.

Veracyte, Inc. and GE Announce Research Collaboration

Veracyte, Inc. and GE announced a research collaboration to develop new solutions that can improve disease diagnosis. Veracyte will collaborate with GE Ventures, GE Healthcare, and the GE Global Research Center to explore the feasibility of combining Veracyte's genomic technology with GE Healthcare's digital imaging technology. Through the agreement, Veracyte and GE aim to identify features from raw imaging data that, when combined with genomic information, have the potential to elucidate useful, new information to further address unmet clinical needs.

Veracyte, Inc. Announces Executive Changes

Veracyte, Inc. announced that in connection with his appointment as Senior Vice President, Strategic Finance and Operations, on April 6, 2015, Duncan T. Powell ceased to serve as the Principal Accounting Officer. Also on April 6, 2015, the Board of Directors of the company appointed Shelly D. Guyer, the company's Chief Financial Officer, to serve in the additional position of principal accounting officer. Ms. Guyer has served as the company's Chief Financial Officer since April 2013.

Similar Private Companies By Industry

Company Name Region
Zassi Holdings, Inc. United States
Thermionics Corporation United States
Orthopedic Designs North America, Inc. United States
Innovia LLC United States
HemoCleanse, Inc. United States

Recent Private Companies Transactions

September 4, 2014
Allegro Diagnostics Corp.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Veracyte, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at